Prophylaxis in people with haemophilia
Authors:
- 1 January 2009
- journal article
- review article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 101 (04) , 674-681
Abstract
Summary: A four-decade clinical experience and recent evidence from randomised controlled studies definitively recognised primary prophylaxis, i.e. the regular infusion of factor concentrates started after the first haemarthrosis and/or before the age of two years, as the first-choice treatment in children with severe haemophilia. The available data clearly show that preventing bleeding since an early age enables to avoid or reduce the clinical impact of muscle-skeletal impairment from haemophilic arthropathy and the related consequences in psycho-social development and quality of life of these patients. In this respect, the aim of secondary prophylaxis, defined as regular long-term treatment started after the age of two years or after two or more joint bleeds, is to avoid (or delay) the progression of arthropathy. The clinical benefits of secondary prophylaxis have been less extensively studied, especially in adolescents and adults; also in the latter better outcomes and quality of life for earlier treatment have been reported. This review summarises evidence from literature and current clinical strategies for prophylactic treatment in patients with severe haemophilia, also focusing on challenges and open issues (optimal regimen and implementation, duration of treatment, long-term adherence and outcomes, cost-benefit ratios) in this setting.Keywords
This publication has 47 references indexed in Scilit:
- Back to the future: a recent history of haemophilia treatmentHaemophilia, 2008
- Including the life-time cumulative number of joint bleeds in the definition of primary prophylaxisThrombosis and Haemostasis, 2008
- Prevention of bleeding in haemophilia: trends, overcoming barriers and future treatment optionsHaemophilia, 2007
- Pathogenesis of haemophilic arthropathyHaemophilia, 2006
- Current co‐ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management)Haemophilia, 2006
- Secondary prophylaxis therapy: what are the benefits, limitations and unknowns?Haemophilia, 2004
- Experience of prophylaxis treatment in children with severe haemophiliaHaemophilia, 2002
- Long‐term outcome of individualized prophylactic treatment of children with severe haemophiliaBritish Journal of Haematology, 2001
- When should prophylactic treatment in patients with haemophilia A and B start?— The German experienceHaemophilia, 1998
- Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and BJournal of Internal Medicine, 1992